Biocure Technology Inc. CUREX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 183.60K | 89.00K | 14.60K | 26.30K | 4.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 183.60K | 89.00K | 14.60K | 26.30K | 4.60K |
| Operating Income | -183.60K | -89.00K | -14.60K | -26.30K | -4.60K |
| Income Before Tax | -1.61M | -810.00K | -20.40K | -33.90K | -15.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.61M | -810.00K | -20.40K | -33.90K | -15.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.61M | -810.00K | -20.40K | -33.90K | -15.50K |
| EBIT | -183.60K | -89.00K | -14.60K | -26.30K | -4.60K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.08 | -0.04 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.08 | -0.04 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 20.21M | 20.21M | 20.26M | 16.10M | 12.13M |
| Average Diluted Shares Outstanding | 20.21M | 20.21M | 20.26M | 16.10M | 12.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |